for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE.N

Latest Trade

37.49USD

Change

-0.31(-0.82%)

Volume

6,163,257

Today's Range

37.35

 - 

37.88

52 Week Range

27.89

 - 

40.93

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
37.80
Open
37.79
Volume
6,163,257
3M AVG Volume
530.31
Today's High
37.88
Today's Low
37.35
52 Week High
40.93
52 Week Low
27.89
Shares Out (MIL)
5,556.88
Market Cap (MIL)
210,050.10
Forward P/E
--
Dividend (Yield %)
4.02

Next Event

Pfizer Inc at EBD Group BIO-Europe (Virtual)

Latest Developments

More

Pfizer Says Phase 2/3 Trial Of COVID-19 Vaccine Has Enrolled 39,862 Participants

Pfizer Announces Positive Phase 3 Top-Line Results For Once-Weekly Investigational LongActing Human Growth Hormone To Treat Children With Growth Hormone Deficiency

Exact Sciences And Pfizer Extend And Amend Cologuard Promotion Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Industry

Biotechnology & Drugs

Contact Info

235 E 42ND ST

NEW YORK, NY

10017-5703

United States

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Albert Bourla

Chairman of the Board, Chief Executive Officer

John D. Young

Chief Business Officer, Group President

Frank A. D'Amelio

Chief Financial Officer, Executive Vice President - Business Operations and Global Supply

Angela Hwang

Group President, Pfizer Biopharmaceuticals Group

Dawn Rogers

Chief Human Resource Officer, Executive Vice President

Key Stats

2.61 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

52.5K

2018

53.6K

2019

51.8K

2020(E)

49.3K
EPS (USD)

2017

2.650

2018

3.000

2019

2.950

2020(E)

2.904
Price To Earnings (TTM)
15.38
Price To Sales (TTM)
4.27
Price To Book (MRQ)
3.26
Price To Cash Flow (TTM)
10.89
Total Debt To Equity (MRQ)
98.88
LT Debt To Equity (MRQ)
78.54
Return on Investment (TTM)
10.32
Return on Equity (TTM)
8.31

Latest News

Latest News

Pfizer, BioNTech start combined trials of COVID-19 vaccine candidate in Japan

Pfizer Inc and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the coronavirus.

GLOBAL MARKETS-Asian markets jump on vaccine, U.S. aid hopes; China data caps gains

Asian markets advanced toward a recent 2-1/2-year peak on Monday powered by hopes of a U.S. fiscal package and expectations of a coronavirus vaccine by the end of this year, though gains were held back by weaker-than-expected Chinese economic data.

GLOBAL MARKETS-Asian markets jump on vaccine, U.S. aid hopes; gains capped by China data

Asian markets advanced toward a recent 2-1/2-year peak on Monday powered by hopes of a U.S fiscal package and expectations of a coronavirus vaccine by the end of this year, though weaker-than-expected Chinese data capped gains.

GLOBAL MARKETS-Asian markets start on firm footing on vaccine, U.S. aid hopes

Asian markets started higher on Monday, buoyed by hopes of a U.S fiscal package before the U.S. presidential elections next month and expectations of a coronavirus vaccine by the end of this year, though the mood was still cautious as infections jump.

Pfizer says earliest U.S. filing for COVID-19 vaccine would be late November

Pfizer Inc <PFE.N> said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year.

EMERGING MARKETS-Latam FX up on vaccine optimism, Chile's peso breaks 4-day losing streak

* Chilean peso up after central bank leaves rates unchanged * Argentina central bank lowers Leliq rate to 36% * Mexican peso outperforms Latam peers for the week (Updates prices throughout) By Shreyashi Sanyal Oct 16 (Reuters) - Latin American currencies rose on Friday after...

EMERGING MARKETS-Latam FX rises on vaccine hopes, Chile's peso bucks 4-day losing streak

* Chilean peso up after central bank leaves rates unchanged * Argentina central bank lowers Leliq rate to 36% * Mexican peso outperforms Latam peers for the week By Shreyashi Sanyal Oct 16 (Reuters) - Latin American currencies rose on Friday after Pfizer said it could apply...

US STOCKS SNAPSHOT-Wall St climbs on vaccine hopes, upbeat retail sales data

U.S. stocks opened higher on Friday as Pfizer said it could apply for emergency use of its COVID-19 vaccine candidate as early as November and data showed stronger-than-expected retail sales growth last month.

BRIEF-Pfizer Says Could Apply For U.S. Emergency Authorization For Vaccine In Third Week Of November

* PFIZER SAYS AN OPEN LETTER FROM PFIZER CHAIRMAN AND CEO ALBERT BOURLA

Pfizer says could apply for U.S. emergency use approval for vaccine in late November

Pfizer Inc said on Friday it would apply for emergency use in the United States of its COVID-19 vaccine candidate being developed along with Germany's BioNTech SE as soon as a safety milestone is achieved in the third week of November. (Reporting by Manojna Maddipatla in...

Canada to review Moderna's COVID-19 vaccine candidate in real time

Moderna Inc said on Tuesday Canada's health ministry will review its experimental COVID-19 vaccine in real time, becoming the third vaccine maker to be accepted by the country for the process that may speed up approval.

Pfizer to enroll kids as young as 12 in COVID-19 vaccine study

Pfizer Inc will enroll participants as young as 12 in its large, late-stage COVID-19 vaccine trial to understand how it works in a wider age group.

Pfizer to enroll kids as young as 12 in COVID-19 vaccine study

Pfizer Inc will enroll participants as young as 12 in its large, late-stage COVID-19 vaccine trial to understand how it works in a wider age group.

Mexico says has accord with Pfizer for 34.4 mln coronavirus vaccines

Mexican Foreign Minister Marcelo Ebrard said on Tuesday that Mexico has an agreement with pharmaceutical company Pfizer for up to 34.4 million vaccines against COVID-19.

New Zealand signs deal with Pfizer, BioNTech for COVID-19 vaccine

The New Zealand government signed a deal on Monday to buy 1.5 million COVID-19 vaccines from Pfizer Inc and Germany's BioNTech, with delivery potentially as early as the first quarter of 2021.

Health Canada to start real-time review of Pfizer-BioNTech COVID-19 vaccine

Health Canada will start a real-time review of Germany's BioNTech SE and Pfizer Inc's experimental COVID-19 vaccine, the companies said on Friday.

Pfizer, BioNTech applies to Health Canada for rolling approval for COVID-19 vaccine

Pfizer Inc and Germany's BioNTech SE said on Friday they have started a rolling submission to Health Canada for their experimental COVID-19 vaccine.

Pfizer's breast cancer drug Ibrance fails late-stage study

Pfizer Inc said on Friday its cancer drug Ibrance did not meet the main goal in a late-stage trial in patients with a type of breast cancer, the latest setback in the company's attempt to expand the use of the drug to treat early stages of the disease.

Pfizer's Ibrance fails breast cancer trial

Pfizer Inc said on Friday its cancer drug Ibrance did not meet the main goal in a late-stage trial in women with a type of breast cancer. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)

U.S. vaccine program head Slaoui expects Pfizer, Moderna vaccine data readouts in November-December

The chief adviser for the U.S. government's Operation Warp Speed COVID-19 vaccine program, Moncef Slaoui, on Tuesday said efficacy data readouts are expected from Pfizer Inc and Moderna Inc between next month and December.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up